BOLD Audentes Therapeutics Inc.

39.94
+1.14  (+3%)
Previous Close 38.8
Open 39.21
Price To Book 4.4
Market Cap 1768960893
Shares 44,290,458
Volume 332,532
Short Ratio
Av. Daily Volume 550,536

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented at WMS October 1-5, 2019.
AT132 - ASPIRO
X-Linked Myotubular Myopathy
Phase 1/2 trial to be initiated 4Q 2019.
AT702
Duchenne Muscular Dystrophy (DMD)

Latest News

  1. Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT
  2. Audentes Therapeutics, Inc. (BOLD) Q1 2019 Earnings Call Transcript
  3. Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
  4. Audentes Therapeutics: 1Q Earnings Snapshot
  5. Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  6. Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD)
  7. Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
  8. Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
  9. Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  10. Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
  11. Estimating The Fair Value Of Audentes Therapeutics, Inc. (NASDAQ:BOLD)
  12. Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
  13. 4 Gene Therapy Players Likely to Become Buyout Targets in 2019
  14. Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy
  15. Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
  16. Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex — New Research Emphasizes Economic Growth
  17. Spark Unlikely To Get A Better Bid — But These Stocks Could Be In Play
  18. 10 Stocks For The Gene Therapy Revolution